Latest News

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of...

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bact

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Assoc...

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Associatio

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the...

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Trea

Teva Reports First Quarter 2021 Financial Results

Teva Reports First Quarter 2021 Financial Results

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia ...

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clini

Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults w...

Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with A

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Red...

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reductio

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine)...

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tabl

Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 2...

Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 28, 20

Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, us...

Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to

Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal...

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring